Navigation Links
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Date:3/7/2011

andidate development.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' dependence on sales of Xyrem, and its ability to increase sales of its Xyrem and Luvox CR products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; the uncertain and time-consuming clinical development and regulatory process for its product candidates, including its intranasal clonazepam product candidate; regulatory risks; Jazz Pharmaceuticals' cash flow estimates, the sufficiency of its cash resources; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its quarterly report on Form 10-Q for the quarter ended September 30, 2010 filed with the Securities and Exchange Commission on November 5, 2010.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

JAZZ PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(Unaudited)Three Months Ended December 31,Year Ended December 31,2010200920102009 Revenues: Product sales, net

$
52,357$
37,319$ 170,006$ 115,108 Royalties, net

7286812,6372,203 Contract revenues

2842841,13811,138 Total revenues

53,36938,284173,781128,449 Operating expense
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... and NEW YORK, Sept. 6, 2011 Galenea ... collaboration to identify synaptic dysfunction linked to Huntington,s ... discovery platform.  Mounting evidence indicates that mutant huntingtin ... synaptic function, contributing to the behavioral, cognitive, and ...
... Sept. 6, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... leading domestic developer, manufacturer and marketer of orthopedic implants ... at the Company,s 2011 annual general meeting held in ... Specifically, the shareholders passed resolutions approving: , Re-election ...
Cached Medicine Technology:Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 2Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 3Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 4China Kanghui Holdings Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting 2
(Date:4/17/2014)... show signs of chronic inflammation in non-cancerous prostate tissue ... prostate cancer than those with no inflammation, according to ... the Johns Hopkins Kimmel Cancer Center. , The link ... men with so-called high-grade prostate cancer those with ... the presence of the most aggressive and rapidly growing ...
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... in lasting psychological scars. This has been proved by ... ,This study was conducted by researchers from Columbia ... of Vietnam War veterans were affected by post-traumatic stress ... higher and lower figures were reported by the contradictory ...
... lay siege on the victim's disposition and way of life, ... coolness can act as an effective pain// reliever. Scientists from ... enable feelings of coolness, and bring immense relief to chronic ... improved treatment measures for people suffering long-term pain, as compared ...
... tests and the presence of various microorganisms has forced the ... ,After a media investigation, Mayor Gerald Tremblay requested mayors ... city's 73 outdoor pools. ,"Public health is important ... conference. "We have to make sure that the safety our ...
... said that Canadian parents appear to have a very rosy ... general they rated Canadian children a C when it came ... commissioned by the CMA. ,It was revealed that ... 9% of Canadian parents considered their own children to be ...
... minors has been supported by President George W. Bush ... the "morning-after"// pill. ,Bush’s statement on ... vote on his nominee Andrew von Eschenbach to head ... ,Von Eschenbach, as acting FDA commissioner has supported nonprescription ...
... blood clots are high during air travel, and not with other ... suggesting// that blood clots can from during any form of travel ... ,The study has revealed that traveling for more than four hours ... clot formation. This was substantiated when the research team analyzed 2000 ...
Cached Medicine News:Health News:Two-thirds of outdoor pools in Montreal are closed 2Health News:Bush Supports Restriction to ‘Morning–After’ P 2
... 1 enables hospitals to ... monitors to a single ... temperature monitoring disposale probes ... superior in their manufacture ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
... Excilite- is a portable, compact, lightweight system ... of emitting the same intensity (50 mW/cm) ... a smaller treatment area (30 cm). Excilite- ... to satisfy the most demanding professional users. ...
... advanced system for laser therapy available today. The ... fiber handpiece that allows to perform linear scanning ... 20% of the energy reflected by the skin. ... special gel which optimizes the optical coupling between ...
Medicine Products: